A new name for an old problem. Metabolic dysfunction-associated steatotic liver disease - review of literature
DOI:
https://doi.org/10.12775/QS.2024.17.53023Keywords
metabolic-dysfunction associated steatotic liver disease, MASLD, non-alcoholic fatty liver disease, NAFLDAbstract
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) was previously known as non-alcoholic fatty liver disease (NAFLD). MASLD is one of the most important and leading causes of liver disease worldwide. This disease is a public health challenge in the 21st century.
Aim of the study: This article aims to present the latest literature data on MASLD. The study is intended to show what consequences are associated with changing the name of the disease and this article is purposive to be a vademecum of knowledge for practicing physicians.
Material and methods: Comprehensive literature searches were performed across the main electronic databases of PubMed and GoogleScholar using the keywords: "metabolic-dysfunction associated steatotic liver disease”, “MASLD”, “non-alcoholic fatty liver disease” and “NAFLD”
Conclusions: Most patients do not report any symptoms. It is important to identify patients at increased risk of MASLD. A fundamental role in prevention and treatment is lifestyle changes. The pharmacological approach includes among others use of antidiabetic drugs and treatment of other associated states.
References
Manikat R, Ahmed A, Kim D. Up-to-date global epidemiology of nonalcoholic fatty liver disease. Hepatobiliary Surg Nutr. 2023;12(6):956-959. doi:10.21037/hbsn-23-548
Eskridge W, Cryer DR, Schattenberg JM, et al. Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis: The Patient and Physician Perspective. J Clin Med. 2023;12(19):6216. Published 2023 Sep 26. doi:10.3390/jcm12196216
Milić S, Stimac D. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment. Dig Dis. 2012;30(2):158-162. doi:10.1159/000336669
Iqbal U, Perumpail BJ, Akhtar D, Kim D, Ahmed A. The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease. Medicines. 2019; 6(1):41. https://doi.org/10.3390/medicines6010041
Paik JM, Henry L, Younossi Y, Ong J, Alqahtani S, Younossi ZM. The burden of nonalcoholic fatty liver disease (NAFLD) is rapidly growing in every region of the world from 1990 to 2019. Hepatol Commun. 2023;7(10):e0251. Published 2023 Oct 2. doi:10.1097/HC9.0000000000000251
Targher G, Corey KE, Byrne CD, Roden M. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599-612. doi:10.1038/s41575-021-00448-y
Zhang X, Ha S, Lau HC, Yu J. Excess body weight: Novel insights into its roles in obesity comorbidities. Semin Cancer Biol. 2023;92:16-27. doi:10.1016/j.semcancer.2023.03.008
Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11-20. doi:10.1038/nrgastro.2017.109
Lu FB, Hu ED, Xu LM, et al. The relationship between obesity and the severity of non-alcoholic fatty liver disease: systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2018;12(5):491-502. doi:10.1080/17474124.2018.1460202
Li Y, Yang P, Ye J, Xu Q, Wu J, Wang Y. Updated mechanisms of MASLD pathogenesis. Lipids Health Dis. 2024;23(1):117. Published 2024 Apr 22. doi:10.1186/s12944-024-02108-x
. Marjot T, Moolla A, Cobbold JF, Hodson L, Tomlinson JW. Nonalcoholic Fatty Liver Disease in Adults: Current Concepts in Etiology, Outcomes, and Management. Endocr Rev. 2020;41(1):bnz009. doi:10.1210/endrev/bnz009
Maldonado-Rojas ADC, Zuarth-Vázquez JM, Uribe M, Barbero-Becerra VJ. Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents. Ann Hepatol. 2024;29(2):101182. doi:10.1016/j.aohep.2023.101182
Zhang J, Zhao Y, Xu C, et al. Association between serum free fatty acid levels and nonalcoholic fatty liver disease: a cross-sectional study. Sci Rep. 2014;4:5832. Published 2014 Jul 25. doi:10.1038/srep05832
Lee KC, Wu PS, Lin HC. Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis. Clin Mol Hepatol. 2023;29(1):77-98. doi:10.3350/cmh.2022.0237
Sakurai Y, Kubota N, Yamauchi T, Kadowaki T. Role of Insulin Resistance in MAFLD. Int J Mol Sci. 2021;22(8):4156. Published 2021 Apr 16. doi:10.3390/ijms22084156
Fujii H, Kawada N, Japan Study Group Of Nafld Jsg-Nafld. The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease. Int J Mol Sci. 2020;21(11):3863. Published 2020 May 29. doi:10.3390/ijms21113863
Huneault HE, Ramirez Tovar A, Sanchez-Torres C, Welsh JA, Vos MB. The Impact and Burden of Dietary Sugars on the Liver. Hepatol Commun. 2023;7(11):e0297. Published 2023 Nov 6. doi:10.1097/HC9.0000000000000297
Cortez-Pinto H, Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol. 2004;18(6):1089-1104. doi:10.1016/j.bpg.2004.06.021
Rinella ME. Nonalcoholic fatty liver disease: a systematic review [published correction appears in JAMA. 2015 Oct 13;314(14):1521]. JAMA. 2015;313(22):2263-2273. doi:10.1001/jama.2015.5370
Ajmera V, Loomba R. Imaging biomarkers of NAFLD, NASH, and fibrosis. Mol Metab. 2021;50:101167. doi:10.1016/j.molmet.2021.101167
Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024;59(2):150-156. doi:10.1111/apt.17846
Platek AE, Szymanska A. Metabolic dysfunction-associated steatotic liver disease as a cardiovascular risk factor. Clin Exp Hepatol. 2023;9(3):187-192. doi:10.5114/ceh.2023.130744
Danpanichkul P, Suparan K, Kim D, Wijarnpreecha K. What Is New in Metabolic Dysfunction-Associated Steatotic Liver Disease in Lean Individuals: From Bench to Bedside. J Clin Med. 2024;13(1):278. Published 2024 Jan 3. doi:10.3390/jcm13010278
Vilarinho S, Ajmera V, Zheng M, Loomba R. Emerging Role of Genomic Analysis in Clinical Evaluation of Lean Individuals With NAFLD. Hepatology. 2021;74(4):2241-2250. doi:10.1002/hep.32047
Fraile JM, Palliyil S, Barelle C, Porter AJ, Kovaleva M. Non-Alcoholic Steatohepatitis (NASH) - A Review of a Crowded Clinical Landscape, Driven by a Complex Disease. Drug Des Devel Ther. 2021;15:3997-4009. Published 2021 Sep 22. doi:10.2147/DDDT.S315724
Portincasa P, Khalil M, Mahdi L, Perniola V, Idone V, Graziani A, Baffy G, Di Ciaula A. Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options. International Journal of Molecular Sciences. 2024; 25(11):5640. doi.org/10.3390/ijms25115640
Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol. 2009;51(2):371-379. doi:10.1016/j.jhep.2009.03.019
Zeng J, Fan JG, Francque SM. Therapeutic management of metabolic dysfunction associated steatotic liver disease. United European Gastroenterol J. 2024;12(2):177-186. doi:10.1002/ueg2.12525
Björkström K, Widman L, Hagström H. Risk of hepatic and extrahepatic cancer in NAFLD: A population-based cohort study. Liver Int. 2022;42(4):820-828. doi:10.1111/liv.15195
Ahmed IA, Mikail MA, Mustafa MR, Ibrahim M, Othman R. Lifestyle interventions for non-alcoholic fatty liver disease. Saudi J Biol Sci. 2019;26(7):1519-1524. doi:10.1016/j.sjbs.2018.12.016
Pouwels S, Sakran N, Graham Y, et al. Non-alcoholic fatty liver disease (NAFLD): a review of pathophysiology, clinical management and effects of weight loss. BMC Endocr Disord. 2022;22(1):63. Published 2022 Mar 14. doi:10.1186/s12902-022-00980-1
Rong L, Zou J, Ran W, et al. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023;13:1087260. Published 2023 Jan 16. doi:10.3389/fendo.2022.1087260
Romero-Gómez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017;67(4):829-846. doi:10.1016/j.jhep.2017.05.016
Shen H, Rodriguez AC, Shiani A, et al. Association between caffeine consumption and nonalcoholic fatty liver disease: a systemic review and meta-analysis. Therap Adv Gastroenterol. 2016;9(1):113-120. doi:10.1177/1756283X15593700
Nagashimada M, Ota T. Role of vitamin E in nonalcoholic fatty liver disease. IUBMB Life. 2019;71(4):516-522. doi:10.1002/iub.1991
Perumpail BJ, Li AA, John N, et al. The Role of Vitamin E in the Treatment of NAFLD. Diseases. 2018;6(4):86. Published 2018 Sep 24. doi:10.3390/diseases6040086
Vadarlis A, Antza C, Bakaloudi DR, et al. Systematic review with meta-analysis: The effect of vitamin E supplementation in adult patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2021;36(2):311-319. doi:10.1111/jgh.15221
Chan WK, Chuah KH, Rajaram RB, Lim LL, Ratnasingam J, Vethakkan SR. Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review. J Obes Metab Syndr. 2023;32(3):197-213. doi:10.7570/jomes23052
Ciardullo S, Muraca E, Vergani M, Invernizzi P, Perseghin G. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions. Gastroenterol Rep (Oxf). 2024;12:goae029. Published 2024 Apr 26. doi:10.1093/gastro/goae029
Sumida Y, Yoneda M. Current and future pharmacological therapies for NAFLD/NASH. J Gastroenterol. 2018;53(3):362-376. doi:10.1007/s00535-017-1415-1
Huttasch M, Roden M, Kahl S. Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?. Metabolism. Published online May 21, 2024. doi:10.1016/j.metabol.2024.155937
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Adrian Kruszewski, Anna Dąbrowska, Paulina Przybysz, Maja Kucharska, Monika Szyszka, Natalia Paduszyńska, Karolina Błaszczak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 211
Number of citations: 0
